Cramer thinks pros are so eager to buy Alibaba they’re willing to throw away perfectly good stocks. That’s silly.» Read More
Amgen Inc. fell$. 31 or. 2 percent, to $137.70. Biogen Idec fell $5.99 or 1.8 percent, to $328.84. Celgene Corp. fell$. 70 or. 7 percent, to $93.23.
Amgen Inc. fell$. 57 or. 4 percent, to $138.01. Biogen Idec fell $9.29 or 2.7 percent, to $334.83. Celgene Corp. fell $1.01 or 1.1 percent, to $93.93.
Amgen Inc. rose$. 02 or percent, to $138.60. Biogen Idec fell $4.21 or 1.2 percent, to $339.91. Celgene Corp. fell$. 66 or. 7 percent, to $94.28.
Amgen Inc. rose$. 42 or. 3 percent, to $139.00. Biogen Idec fell$. 92 or. 3 percent, to $343.20. Celgene Corp. fell$. 47 or. 5 percent, to $94.47.
Amgen Inc. rose$. 62 or. 4 percent, to $138.58. Biogen Idec rose $1.44 or. 4 percent, to $344.12. Celgene Corp. fell$. 15 or. 2 percent, to $94.94.
Amgen Inc. rose$. 51 or. 4 percent, to $138.47. Biogen Idec rose$. 64 or. 2 percent, to $343.32. Celgene Corp. fell$. 31 or. 3 percent, to $94.78.
Amgen Inc. rose$. 62 or. 4 percent, to $138.58. Biogen Idec rose $1.16 or. 3 percent, to $343.84. Celgene Corp. rose$. 15 or. 2 percent, to $95.24.
The dynamics in the market are changing. And Cramer says investors need to change, accordingly.
The stocks analysts loved going into the year — their must-buys if you will — have delivered big time. USA Today reports.
Goldman Sachs and Asian tech name, Baidu were in the "buy" category, while Netflix and utilities exchange-traded fund XLU were among the stocks to "sell."
The stock market has been able to bounce back from every negative headline and set fresh record highs. But, some stocks have fared better than others.
Some of Wednesday's midday movers:
Apple touched a fresh high Wednesday along with a handful of other companies:
Some of Tuesday's midday movers:
Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.
Did you catch Priceline earnings? Jim Cramer thinks there’s an important lesson for Apple investors.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.
July 24- Celgene Corp posted a 25 percent rise in quarterly profit, beating the average analyst estimate by a cent, helped by robust sales of its flagship cancer drug, Revlimid. The U.S. biotechnology company also raised its 2014 adjusted earnings outlook to $3.60- $3.65 per share, from $3.50- $3.60, and revenue forecast to $7.60 billion from $7.50 billion.
If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.